Postpartum cells derived from placental tissue, and methods of making and using the same

Patent metadata

Field	Value
Publication number	US-10220059-B2
Application number	US-201715443602-A
Country	US
Kind code	B2
Filing date	Feb 27, 2017
Priority date	Jun 27, 2003
Publication date	Mar 5, 2019
Grant date	Mar 5, 2019

Abstract

Cells derived from postpartum placenta and methods for their isolation are provided by the invention. The invention further provides cultures and compositions of the placenta-derived cells. The placenta-derived cells of the invention have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications.

First claim

What is claimed:

1. An extracellular matrix composition comprising isolated human placenta-derived cells and extracellular matrix produced by a population of the isolated human placenta-derived cells, wherein the isolated human placenta-derived cells are derived from human postpartum placenta tissue substantially free of blood, wherein the placenta-derived cell self-renews and expands in culture, is multipotent, grows in about 5% to about 20% oxygen, and further comprises the following characteristics:
a) produces CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2, HLA-A,B,C, and granulocyte chemotactic protein-2 (GCP-2);
b) does not produce CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G or HLA-DR-DP, DQ, as detected by flow cytometry; and
c) expresses, relative to a human fibroblast, mesenchymal stem cell, or iliac crest bone marrow cell, increased levels of oxidized low density lipoprotein receptor 1 and renin.

2. The extracellular matrix composition of claim 1 , wherein the isolated human placenta-derived cell in the composition is a cryopreserved cell.

3. The extracellular matrix composition of claim 1 , wherein the placenta-derived cell further comprises the following characteristics:
d) lacks production of GRO-alpha and oxidized low density lipoprotein receptor, as detected by flow cytometry
e) secretes of monocyte chemotactic protein 1 (MCP-1), interleukin-6 (IL-6), interleukin 8 (IL8), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), heparin-binding epidermal growth factor (HB-EGF), brain-derived neurotrophic factor (BDNF), tissue inhibitor of matrix metalloproteinase 1 (TIMP1), thrombopoietin (TPO), macrophage inflammatory protein 1alpha (MIP1a), Rantes (regulated on activation, normal T cell expressed and secreted), thymus and activation-regulated chemokine (TARC), and Eotaxin; and
f) lack of secretion of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), angiopoietin 2 (ANG2), platelet derived growth factor (PDGF-bb), transforming growth factor beta2 (TGFbeta2), macrophage inflammatory protein 1beta (MIP1b), I309, and macrophage-derived chemokine (MDC), as detected by ELISA.

4. The extracellular matrix composition of claim 1 , wherein the placenta-derived cell is of a neonatal origin.

5. The extracellular matrix composition of claim 1 , wherein said placenta-derived cell is of a maternal origin.

6. The extracellular matrix composition of claim 1 , wherein the placenta-derived cell has the ability to differentiate into a mesodermal, ectodermal, or endodermal phenotype.

7. The extracellular matrix composition of claim 1 , wherein the placenta-derived cell can undergo at least 40 population doublings in culture.

8. The extracellular matrix composition claim 1 , further comprising genetically engineering the placenta-derived cell to produce a protein of interest.

9. The extracellular matrix composition of claim 1 , wherein the placenta-derived cell is identified by ATCC Accession No. PTA-6074.

10. The extracellular matrix composition of claim 1 , wherein the placenta-derived cell is identified by ATCC Accession No. PTA-6075.

11. The extracellular matrix composition of claim 1 , wherein the placenta-derived cell is identified by ATCC Accession No. PTA-6079.

12. A matrix comprising the extracellular matrix composition of claim 1 .

13. The matrix of claim 12 , wherein said matrix is a three-dimensional scaffold.

14. The matrix of claim 13 comprising a nonwoven scaffold, a 35/65 PCL/PGA foam, an in situ polymerizable gel, or a self-assembling peptide hydrogel.

Assignees

• Depuy Synthes Products Inc

Inventors

• Kihm Anthony J
• Harris Ian Ross
• Mistry Sanjay
• Harmon Alexander M
• Messina Darin J
• Seyda Agnieszka
• Yi Chin-Feng
• Gosiewska Anna

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P39/06

  Free radical scavengers or antioxidants · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title